trial · primary record
Universal CD19-specific CAR gene-engineered T cells
B Cell Malignancies
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2030-12-31 |
| Primary endpoint | Safety of 4SCAR19U CAR-T cells infusion |
| Registry ID | NCT05995015 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:21.391Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05995015
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.